市場調査レポート

商品コード

1649617

抗ウイルス薬の市場規模、シェア、成長分析：適応症別、患者タイプ別、製品タイプ別、薬剤タイプ別、エンドユーザー別、流通チャネル別、地域別 - 産業予測、2025年～2032年

Antiviral Drugs Market Size, Share, and Growth Analysis, By Indication (Influenza, Human Immunodeficiency Virus ), By Patient Type, By Products, By Drug Type, By End User, By Distribution Channel, By Region - Industry Forecast 2025-2032

出版日: 2025年02月02日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 763,518円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 893,172円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,022,826円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
目次

概要

サンプル依頼リストに入れる

抗ウイルス薬市場規模は2023年に380億米ドルと評価され、予測期間（2025～2032年）のCAGRは3.5%で、2024年の393億3,000万米ドルから2032年には517億9,000万米ドルに成長する見通しです。

世界の抗ウイルス薬市場は、HIV/AIDS、B型肝炎、C型肝炎、インフルエンザなどのウイルス感染症の罹患率上昇に牽引され、大幅な成長が見込まれています。この需要の急増により、製薬会社は研究開発に多額の投資を行い、有効性の向上、副作用の軽減、患者のコンプライアンス向上を約束する革新的な抗ウイルス療法に注力しています。新薬標的の発見により治療の選択肢が広がる一方、ウイルス感染に対する意識の高まりにより、早期介入の重要性が強調されています。さらに、政府の支援策や研究への資金援助が市場の成長をさらに後押ししています。官民連携による取り組みが医薬品へのアクセスを向上させる一方、臨床試験への多額の投資がアンメットメディカルニーズに対応し、市場の拡大軌道を確固たるものにしています。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主な市場企業が採用した戦略
市場の最近の動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 会社概要
- 製品ポートフォリオ分析
- セグメント別シェア分析
- 収益の前年比比較（2022-2024）

主要企業プロファイル

Gilead Sciences Inc.（USA）
AbbVie, Inc.（USA）
GlaxoSmithKline（UK）
Merck& C.O., Inc.（USA）
Janssen Pharmaceuticals, Inc.（USA）
Bristol-Meyrs Squibb Company（USA）
Mylan N. V.（Netherlands）
Novartis AG（Switzerland）
AstraZeneca（UK）
Pfizer Inc.（USA）
Cipla Inc.（India）
Johnson & Johnson Services, Inc.（USA）
Aurobindo Pharma（India）
Merck MRK（USA）
Reddy Laboratories Limited（India）
Hoffmann-La Roche Ltd.（Switzerland）
Altesa Biosciences Inc.（USA）
Sanofi（France）
Eli Lilly（USA）
Roche（Switzerland）

結論と推奨事項

Product Code: SQMIG35B2171

Antiviral Drugs Market size was valued at USD 38.0 billion in 2023 and is poised to grow from USD 39.33 billion in 2024 to USD 51.79 billion by 2032, growing at a CAGR of 3.5% during the forecast period (2025-2032).

The global antiviral drugs market is poised for considerable growth, driven by rising incidence rates of viral infections such as HIV/AIDS, hepatitis B and C, and influenza. This surge in demand has prompted pharmaceutical companies to invest heavily in research and development, focusing on innovative antiviral therapies that promise increased efficacy, fewer side effects, and better patient compliance. The discovery of new drug targets has widened treatment options, while heightened awareness around viral infections has underscored the importance of early intervention. Additionally, supportive government initiatives and funding for research have further propelled market growth. Collaborative efforts within public-private partnerships are enhancing drug accessibility, while significant investments in clinical trials are addressing unmet medical needs, solidifying the market's expansion trajectory.

Top-down and bottom-up approaches were used to estimate and validate the size of the Antiviral Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Antiviral Drugs Market Segments Analysis

Global Antiviral Drugs Market is segmented by Indication, Patient Type, Products, Drug Type, End User, Distribution Channel and Region. Based on Indication, the market is segmented into Influenza, Human Immunodeficiency Virus (HIV), Hepatitis C Virus, Herpes Simplex Virus, Human Cytomegalovirus (HCMV), Varicella-Zoster Virus (VZV), Hepatitis B Virus, Respiratory Syncytial Virus, Coronavirus Infection and Others. Based on Patient Type, the market is segmented into Child, Adult and Geriatric. Based on Products, the market is segmented into Oral, Topical and Parenteral. Based on Drug Type, the market is segmented into Generic and Branded. Based on End User, the market is segmented into Hospital, Clinics, Home Healthcare, Speciality Centers, Ambulatory Centers and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Antiviral Drugs Market

The widespread incidence of HIV/AIDS has significantly heightened the demand for antiretroviral therapies, thereby propelling the growth of the antiviral drugs market. The advent of highly active antiretroviral therapy (HAART) has transformed the treatment landscape for HIV/AIDS, providing effective management solutions that enhance the quality of life and extend the life expectancy of those affected by the virus. This progress not only underscores the critical need for innovative antiviral drugs but also fuels investment and research in this sector, further catalyzing market expansion as healthcare providers strive to offer comprehensive care for individuals living with HIV/AIDS.

Restraints in the Antiviral Drugs Market

The antiviral drugs market faces significant restraints primarily due to the stringent and time-consuming regulatory approval processes. Manufacturers encounter challenges in meeting demanding safety, efficacy, and quality standards, which can result in considerable delays for the market entry of new antiviral treatments. Such strict regulations not only complicate the approval landscape but can also impede the timely availability of crucial therapies. Adhering to these rigorous regulatory frameworks is essential for ensuring drug safety and effectiveness, yet this compliance can substantially elongate the timelines for both development and approval, ultimately impacting the accessibility of vital antiviral medications for patients in need.

Market Trends of the Antiviral Drugs Market

The antiviral drugs market is currently witnessing a significant shift towards the development of broad-spectrum antiviral medications, reflecting a growing need for effective treatments against a variety of emerging viral infections. This trend is fueled by the limitations of traditional antiviral drug development, which often targets specific strains or types of viruses. Broad-spectrum antivirals present advantages such as cost-effectiveness, rapid responsiveness to outbreaks, and enhanced patient outcomes through their capability to combat multiple viral pathogens simultaneously. Innovations in drug discovery, including the exploration of viral host factors and diverse antiviral mechanisms, are further propelling this market trend, positioning broad-spectrum antivirals as a cornerstone in future antiviral therapies.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Antiviral Drugs Market Size by Indication & CAGR (2025-2032)

Market Overview
Influenza
Human Immunodeficiency Virus (HIV)
Hepatitis C Virus
Herpes Simplex Virus
Human Cytomegalovirus (HCMV)
Varicella-Zoster Virus (VZV)
Hepatitis B Virus
Respiratory Syncytial Virus
Coronavirus Infection
Others

Global Antiviral Drugs Market Size by Patient Type & CAGR (2025-2032)

Market Overview
Child
Adult
Geriatric

Global Antiviral Drugs Market Size by Products & CAGR (2025-2032)

Market Overview
Oral
Topical
Parenteral

Global Antiviral Drugs Market Size by Drug Type & CAGR (2025-2032)

Market Overview
Generic
Branded

Global Antiviral Drugs Market Size by End User & CAGR (2025-2032)

Market Overview
Hospital
Clinics
Home Healthcare
Speciality Centers
Ambulatory Centers
Others

Global Antiviral Drugs Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy

Global Antiviral Drugs Market Size & CAGR (2025-2032)

North America (Indication, Patient Type, Products, Drug Type, End User, Distribution Channel)
- US
- Canada
Europe (Indication, Patient Type, Products, Drug Type, End User, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Indication, Patient Type, Products, Drug Type, End User, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Indication, Patient Type, Products, Drug Type, End User, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Indication, Patient Type, Products, Drug Type, End User, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Gilead Sciences Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck& C.O., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Janssen Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Meyrs Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N. V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Inc. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson Services, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurobindo Pharma (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck MRK (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Reddy Laboratories Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Altesa Biosciences Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

抗ウイルス薬の市場規模、シェア、成長分析：適応症別、患者タイプ別、製品タイプ別、薬剤タイプ別、エンドユーザー別、流通チャネル別、地域別 - 産業予測、2025年～2032年

Antiviral Drugs Market Size, Share, and Growth Analysis, By Indication (Influenza, Human Immunodeficiency Virus ), By Patient Type, By Products, By Drug Type, By End User, By Distribution Channel, By Region - Industry Forecast 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

抗ウイルス薬市場規模：適応症別& CAGR（2025-2032）

抗ウイルス薬市場規模：患者タイプ別& CAGR（2025-2032）

抗ウイルス薬市場規模：製品タイプ別& CAGR（2025-2032）

抗ウイルス薬市場規模：薬剤タイプ別& CAGR（2025-2032）

抗ウイルス薬市場規模：エンドユーザー別& CAGR（2025-2032）

抗ウイルス薬市場規模：流通チャネル別& CAGR（2025-2032）

抗ウイルス薬市場規模：地域別& CAGR（2025-2032）